LEQEMBI(R) Pen (Subcutaneous Formulation of LEQEMBI(R)) Approved in Japan for the Treatment of Early Alzheimer's Disease
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that "LEQEMBI(R) Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (AB) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration.